secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001140361-22-044043
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals completes acquisition of Renovacor; gains BAG3-DCM gene therapy REN-001
--------------------------------------------------------------------------------

- Renovacor shareholders received 0.1763 shares of Rocket common stock per Renovacor share.
- Acquisition extends Rocket's AAV-based cardiac gene therapy leadership with REN-001 targeting BAG3-associated dilated cardiomyopathy.
- Rocket gains Renovacor's IP, scientific collaborators, and BAG3-DCM expertise.
- Renovacor shares ceased trading on NYSE; Rocket continues on Nasdaq as RCKT.
- Stockholders approved the share issuance proposal at Nov 30 special meeting with ~99.9% votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036122044043/0001140361-22-044043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036122044043/brhc10044894_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-044043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer